 |
daxibotulinumtoxinA |
|---|---|
| Trade Name | not avaiable |
| Orphan Indication | 1-(2-Nitro-imidazolyl)-3-[18F]fluoro-2-propanol;1H-1-(3-[18F]fluoro-2-hydroxypropyl)-2-nitroimidazole |
| USA Market Approval | USA |
| USA Designation Date | 2018-01-09 00:00:00 |
| Sponsor | Revance Therapeutics, Inc. 7555 Gateway Boulevard Newark, California, 94560 |
